{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:40:14Z","timestamp":1791290414254,"version":"4.3.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270233"],"award-info":[{"award-number":["82270233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100155"],"award-info":[{"award-number":["82100155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515010829"],"award-info":[{"award-number":["2024A1515010829"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011659"],"award-info":[{"award-number":["2024A1515011659"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05907-z","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:02:53Z","timestamp":1746061373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt\/\u03b2-catenin pathway"],"prefix":"10.1186","volume":"23","author":[{"given":"Suwan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6680","authenticated-orcid":false,"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"1","key":"5907_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194.","journal-title":"Mol Cancer"},{"issue":"1","key":"5907_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"5907_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"5","key":"5907_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"9967","key":"5907_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London England). 2015;385(9967):517\u201328.","journal-title":"Lancet (London England)"},{"issue":"25","key":"5907_CR6","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322\u201331.","journal-title":"Blood"},{"issue":"12","key":"5907_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, et al. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Reviews Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5907_CR8","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"issue":"7786","key":"5907_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576(7786):293\u2013300.","journal-title":"Nature"},{"issue":"7749","key":"5907_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u20134.","journal-title":"Nature"},{"issue":"5","key":"5907_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Reviews Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"5907_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","volume":"37","author":"W Ye","year":"2016","unstructured":"Ye W. The complexity of translating anti-angiogenesis therapy from Basic Science to the clinic. Dev Cell. 2016;37(2):114\u201325.","journal-title":"Dev Cell"},{"issue":"5","key":"5907_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Reviews Clin Oncol. 2018;15(5):310\u201324.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5907_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B. Targeting VEGF\/VEGFR to modulate Antitumor immunity. Front Immunol. 2018;9:978.","journal-title":"Front Immunol"},{"issue":"11","key":"5907_CR15","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150\u201366.","journal-title":"Blood"},{"issue":"10","key":"5907_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol. 2011;11(10):702\u201311.","journal-title":"Nat Rev Immunol"},{"issue":"Pt 2","key":"5907_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Sem Cancer Biol. 2018;52(Pt 2):117\u201324.","journal-title":"Sem Cancer Biol"},{"issue":"2","key":"5907_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8\u2009+\u2009T cells in tumors. J Exp Med. 2015;212(2):139\u201348.","journal-title":"J Exp Med"},{"issue":"3","key":"5907_CR19","first-page":"881","volume":"29","author":"J Wada","year":"2009","unstructured":"Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009;29(3):881\u20138.","journal-title":"Anticancer Res"},{"issue":"2","key":"5907_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539\u201349.","journal-title":"Cancer Res"},{"key":"5907_CR21","doi-asserted-by":"crossref","unstructured":"Dong X, Ren J, Amoozgar Z et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer, 2023, 11 (3).","DOI":"10.1136\/jitc-2022-005583"},{"issue":"11","key":"5907_CR22","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood-2009-11-252460","volume":"116","author":"M Edelbauer","year":"2010","unstructured":"Edelbauer M, Datta D, Vos IH, et al. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood. 2010;116(11):1980\u20139.","journal-title":"Blood"},{"issue":"2","key":"5907_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4049\/jimmunol.0900397","volume":"184","author":"A Basu","year":"2010","unstructured":"Basu A, Hoerning A, Datta D, et al. Cutting edge: vascular endothelial growth factor-mediated signaling in human CD45RO\u2009+\u2009CD4\u2009+\u2009T cells promotes akt and ERK activation and costimulates IFN-gamma production. J Immunol (Baltimore Md: 1950). 2010;184(2):545\u20139.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"5907_CR24","doi-asserted-by":"crossref","unstructured":"Kim CG, Jang M, Kim Y et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol, 2019, 4 (41).","DOI":"10.1126\/sciimmunol.aay0555"},{"issue":"6","key":"5907_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"key":"5907_CR26","doi-asserted-by":"crossref","unstructured":"Allen E, Jabouille A, Rivera LB et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med, 2017, 9 (385).","DOI":"10.1126\/scitranslmed.aak9679"},{"issue":"4","key":"5907_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, et al. Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 Blockade promotes vascular normalization and enhances Antitumor Immune responses in Hepatocellular Carcinoma. Hepatology (Baltimore MD). 2020;71(4):1247\u201361.","journal-title":"Hepatology (Baltimore MD)"},{"key":"5907_CR28","doi-asserted-by":"crossref","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med, 2017, 9 (385).","DOI":"10.1126\/scitranslmed.aak9670"},{"issue":"1","key":"5907_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard Y, Andersson BS, Baysal MA, et al. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023;16(1):108.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"5907_CR30","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin cancer Research: Official J Am Association Cancer Res. 2008;14(22):7272\u201383.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"5907_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","volume":"13","author":"P Bhargava","year":"2011","unstructured":"Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103\u201311.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"5907_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2326-6066.CIR-19-0360","volume":"8","author":"PE de Almeida","year":"2020","unstructured":"de Almeida PE, Mak J, Hernandez G, et al. Anti-VEGF treatment enhances CD8 (+) T-cell antitumor activity by amplifying hypoxia. Cancer Immunol Res. 2020;8(6):806\u201318.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"5907_CR33","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-10-0356","volume":"16","author":"L Gattinoni","year":"2010","unstructured":"Gattinoni L, Ji Y, Restifo NP. Wnt\/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin cancer Research: Official J Am Association Cancer Res. 2010;16(19):4695\u2013701.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"7","key":"5907_CR34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8\u2009+\u2009memory stem cells. Nat Med. 2009;15(7):808\u201313.","journal-title":"Nat Med"},{"issue":"6","key":"5907_CR35","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.4049\/jimmunol.1400465","volume":"193","author":"C Boudousqui\u00e9","year":"2014","unstructured":"Boudousqui\u00e9 C, Danilo M, Pousse L, et al. Differences in the transduction of canonical wnt signals demarcate effector and memory CD8 T cells with distinct recall proliferation capacity. J Immunol (Baltimore Md: 1950). 2014;193(6):2784\u201391.","journal-title":"J Immunol (Baltimore Md: 1950)"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05907-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05907-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05907-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:19:31Z","timestamp":1746519571000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05907-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5907"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05907-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was authorized and supervised by the Ethics Committee of the Zhujiang Hospital of Southern Medical University. All participants provided written informed consent before enrollment. Animal experiments were conducted in line with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}